Previous 10 | Next 10 |
Innovative best-in-class technology solutions continue to offer HCPs a seamless prescribing experience within the EHR workflow ROCHESTER, Mich., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of poi...
ROCHESTER, Mich., Sept. 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that management will participate in the fol...
Analysis finds patent-pending real-world evidence solution successful in identifying HCPs with patients at risk of non-adherence due to unexpected cost. Proactive affordability messaging key for doctors and patients navigating Medicare coverage gaps ROCHESTER, Mich., Aug. ...
Gainers: Euro Tech Holdings ( CLWT ) +63% . Invitae ( NVTA ) +59% . Allego ( ALLG ) +54% . Grove Collaborative ( GROV ) +52% . BioAtla ( BCAB ) +40% . The Trade Desk ( TTD ) +37% . Chicken Soup for the Soul Entert...
Gainers: OraSure Technologies ( OSUR ) +28% . BioAtla ( BCAB ) +24% . Catalyst Pharmaceuticals ( CPRX ) +16% . Clovis Oncology ( CLVS ) +13% . Quanterix ( QTRX ) +13% . Losers: Singular Genomics Systems ( OMIC ...
OptimizeRx ( NASDAQ: OPRX ) stock slumped ~26% premarket on Aug. 10 after Q2 results missed estimates and the company lowered its FY22 outlook, seen below analysts' expectations, citing temporary challenges to life sciences industry. Q2 Non-GAAP EPS declined 60%...
Image source: The Motley Fool. OptimizeRx Corporation (NASDAQ: OPRX) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q2 2022 Earnings Conference Call August 09, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Da...
Revenue Up 3% to $14.0 million, driven by new customer and program launches Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition Generated $4.4 million in cash flow from operations during the first half of 2022 ...
OptimizeRx press release ( NASDAQ: OPRX ): Q2 Non-GAAP EPS of $0.04 (vs. $0.10 Y/Y) misses by $0.05 . Revenue of $14M (+2.9% Y/Y) misses by $3.06M . For FY22, net revenue is expected to be in the range of of $62M to $68M (vs. consensus of $81.47M) For fur...
News, Short Squeeze, Breakout and More Instantly...
OptimizeRx Corporation Company Name:
OPRX Stock Symbol:
NASDAQ Market:
OptimizeRx Corporation Website:
• 84% of Patients Arrive at Doctor Visits Underinformed • Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies • OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client WAL...
2024-06-13 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...